Business
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its CEO, Thomas Jensen, has been invited to present at the upcoming Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. In addition to his presentation, Mr. Jensen will be interviewed by Oxf
About this update from Allarity Therapeutics, Inc.
[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H2n2B7OUZZNZTe8771hvug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"text","content":"","length":48,"tagName":"p"},{"type":"text","content":"TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its CEO, Thomas Jensen, has been invited to present at the upcoming Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global.","length":433,"tagName":"p"},{"type":"text","content":"In addition to his presentation, Mr. Jensen will be interviewed by Oxford Global’s editorial team to provide further insights into Allarity’s research and its innovative DRP® companion diagnostic platform. The interview will be featured on Oxford Global’s online content portal.","length":278,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Event: Biomarkers & Precision Medicine 2025","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Title: A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: Wednesday, October 1, 2025","length":32,"tagName":"p"}]},{"val":[{"type":"text","content":"Time: 4:00 PM","length":13,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":198,"olType":false},{"type":"text","content":"Mr. Jensen will be available for individual meetings during the conference to explore business development prospects. Attendees are encouraged to book one-on-one sessions in advance.","length":182,"tagName":"p"},{"type":"text","content":"About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhi...